NASDAQ:IMMP
Immutep Ltd Stock News
$2.71
-0.0200 (-0.733%)
At Close: Jun 14, 2024
Immutep successfully completes institutional placement and institutional component of entitlement offer
06:00am, Wednesday, 05'th Jun 2024
Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) (Immutep or the Company) is pleased to announce the successful completion of its instituti
SYDNEY, AUSTRALIA, June 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immun
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
08:00am, Wednesday, 15'th May 2024
Media Release Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxel Ongoing
Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial Four of six pat
Immutep Quarterly Activities Report Q3 FY24
08:00am, Monday, 29'th Apr 2024
Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one patient r
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
08:00am, Wednesday, 24'th Apr 2024
Media Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9% respon
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
08:00am, Thursday, 18'th Apr 2024
Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address
SYDNEY, AUSTRALIA, April 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunot
Immutep Announces First Clinical Data from 90mg Dosing of Efti
08:00am, Tuesday, 05'th Mar 2024
SYDNEY, AUSTRALIA, March 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immun
Immutep Quarterly Activities Report Q2 FY24
08:00am, Tuesday, 30'th Jan 2024
Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing P
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
08:00am, Thursday, 04'th Jan 2024
Media Release SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel
Immutep: Upcoming Signals For 2024 (Maintain Buy)
05:04pm, Wednesday, 03'rd Jan 2024
Immutep Limited's lead molecule, eftilagimod, has shown signals of activity in lung cancer and has the potential to be a chemotherapy-free regimen with manageable toxicity. The company has received re
Immutep Advances Towards Phase III Trial for Lung Cancer Treatment with Positive Regulatory Feedback
10:29am, Wednesday, 27'th Dec 2023
New York, December 27, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a trailblazing clinical-stage biotechnology company, has announced encouraging news from the Paul-Ehrlich-Institut (PEI),
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
08:00am, Thursday, 21'st Dec 2023
Media Release SYDNEY, AUSTRALIA, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
08:00am, Thursday, 07'th Dec 2023
Media Release SYDNEY, AUSTRALIA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related